Clinical trial
Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial…
NCT00005049 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00005049 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer |
| Official title | Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Ovarian Cancer, Peritoneal Cavity Cancer, Small Intestine Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, cisplatin, floxuridine |
| Enrollment | 45 |
| Start date | May 1, 1997 |
| Primary completion | Nov 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 6, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: